Sheets Smith Investment Management Grows Stock Position in Insulet Corporation $PODD

Key Points

• Sheets Smith Investment Management increased its holdings in Insulet Corporation by 48.2% during the first quarter, owning 4,641 shares valued at approximately $1.22 million.
• Insulet reported an earnings per share of $1.17 for the quarter, exceeding analysts' expectations of $0.92, with revenues reaching $649.10 million.
• Multiple hedge funds, including Vanguard and American Century Companies, have also increased their stakes in Insulet, indicating growing institutional interest.

Sheets Smith Investment Management raised its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 48.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,641 shares of the medical instruments supplier's stock after buying an additional 1,509 shares during the quarter. Insulet comprises 1.2% of Sheets Smith Investment Management's holdings, making the stock its 23rd largest position. Sheets Smith Investment Management's holdings in Insulet were worth $1,219,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Insulet by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock worth $2,276,553,000 after acquiring an additional 178,976 shares during the last quarter. American Century Companies Inc. raised its stake in Insulet by 34.8% in the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after acquiring an additional 297,734 shares during the last quarter. Groupama Asset Managment raised its stake in Insulet by 0.4% in the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock worth $276,728,000 after acquiring an additional 3,759 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Insulet by 4.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock worth $177,096,000 after acquiring an additional 27,408 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Insulet by 27,298.6% during the first quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock worth $1,744,100,000 after purchasing an additional 661,717 shares during the period.

Insulet Trading Up 0.1%

Shares of Insulet stock opened at $337.94 on Friday. The firm has a 50-day simple moving average of $310.77 and a two-hundred day simple moving average of $291.47. The company has a market cap of $23.79 billion, a P/E ratio of 102.72, a price-to-earnings-growth ratio of 2.80 and a beta of 1.36. Insulet Corporation has a fifty-two week low of $225.28 and a fifty-two week high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company's revenue was up 32.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on PODD. Canaccord Genuity Group lifted their target price on Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Raymond James Financial reaffirmed an "outperform" rating and set a $360.00 target price (up previously from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Oppenheimer lifted their target price on Insulet from $324.00 to $365.00 and gave the stock an "outperform" rating in a report on Monday. Royal Bank Of Canada lifted their target price on Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Finally, The Goldman Sachs Group assumed coverage on shares of Insulet in a report on Friday, May 30th. They issued a "buy" rating and a $380.00 price target on the stock. Sixteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Insulet presently has a consensus rating of "Moderate Buy" and an average price target of $335.12.

Insider Activity at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company's stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.